APA (7th ed.) Citation

M, P., GL, D., E, D., D, Y., Y, C., YD, B., . . . L, L. (2018). Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: An open-label, randomised controlled trial. The Lancet. Infectious diseases, 18(4), 391. https://doi.org/10.1016/S1473-3099(18)30099-9

Chicago Style (17th ed.) Citation

M, Paul, et al. "Colistin Alone Versus Colistin Plus Meropenem for Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: An Open-label, Randomised Controlled Trial." The Lancet. Infectious Diseases 18, no. 4 (2018): 391. https://doi.org/10.1016/S1473-3099(18)30099-9.

MLA (9th ed.) Citation

M, Paul, et al. "Colistin Alone Versus Colistin Plus Meropenem for Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: An Open-label, Randomised Controlled Trial." The Lancet. Infectious Diseases, vol. 18, no. 4, 2018, p. 391, https://doi.org/10.1016/S1473-3099(18)30099-9.